NASADAD

Search
Skip to content
  • Login
  • Home
  • About Us
    • About Us
    • Board of Directors
    • NASADAD Staff
  • Contact Us
  • Mobile Menus
MembersOnly

203a. Buprenorphine Physicians Follow-up Inquiry (5/11/17)

Image September 13, 2017 aaa

You must be logged in to view this content.

Post navigation

Previous Post165. MAT Induction in Jails or Prisons (7/31/17)Next Post181. Impact of Good Samaritan Law (3/4/16)

Sign Up for Our Weekly Newsletter

Select list(s) to subscribe to

By submitting this form, you are consenting to receive marketing emails from: NASADAD, 1919 Pennsylvania Avenue NW, Washington, DC, 20006, http://www.nasadad.org. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
  • Our Members
    • Role of State Alcohol and Drug Agencies
  • NASADAD Annual Meeting
  • Public Policy
    • Substance Use Prevention, Treatment and Recovery Services (SUPTRS) Block Grant
    • NASADAD Fact Sheets
    • Legislative Summaries
    • Federal Budget and Appropriations
    • Letters & Regulatory Comments
    • NASADAD Presentations
    • D.C. Updates
    • Partnerships for Success Information
    • Hot Topics
    • State Specific Information
    • Health Reform Information
    • Members Only
  • Prevention
    • National Prevention Network
    • NPN Conference
    • Innovative Substance Abuse Prevention Programs, Practices and Policies
    • National Prevention Resources
  • Treatment & Recovery
    • National Treatment Network
    • Women’s Services Network
    • Opioid Treatment Network
    • HIV Coordinators
    • Youth Coordinators
    • State Treatment & Recovery Resources
  • Resources
    • NASADAD Reports
    • Federal Resources
    • NASADAD Component Groups
    • Research
  • Job Postings
  • Show Member Menus
© The National Association of State Alcohol and Drug Agency Directors